Oncology development

Rybrevant Faspro’s Head and Neck Cancer Approval and What Phase 3 Will Test

Review the FDA’s accelerated approval of Rybrevant Faspro in previously treated head and neck cancer, the OrigAMI-4 evidence, and what Phase 3 OrigAMI-5 will test.

By Lampgen Clinical Research

Two oncology research professionals review study paperwork beneath the headline “The next test for Rybrevant Faspro” and the subtitle “The Phase 3 confirmatory trial.”
AI-generated editorial illustration for Lampgen Clinical Insights.

3 min read · estimated

Sources
42% objective response56% of responders
In OrigAMI-4, 42% of 102 patients responded. Among responders, 56% had a response lasting at least six months.

What the source reported

On November 5, 2026, the FDA granted accelerated approval to subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that progressed on or after platinum-based chemotherapy and an anti–PD-(L)1 antibody. The indication excludes HPV-associated oropharyngeal squamous cell carcinoma. This is the first Rybrevant Faspro indication outside non-small cell lung cancer. For patients who have progressed after both treatment classes, it adds a targeted option. [1, 2]

Amivantamab binds EGFR and MET, two receptors that can be overexpressed in HNSCC. The approval rested on a single-arm cohort of the open-label Phase 1b/2 OrigAMI-4 study. Among 102 patients, blinded independent central review found a 42% objective response rate (95% CI, 32% to 52%). Among responders, 56% had a response lasting at least six months. The study reported a median follow-up of 11.8 months and excluded patients with prior anti-EGFR therapy from this cohort. The survival estimates describe this cohort. Comparative survival benefit remains an open question. [1, 3, 4]

Safety matters alongside response. Johnson & Johnson reported rash in 79% of treated patients and serious adverse reactions in 39%. The FDA identifies warnings for hypersensitivity and administration-related reactions, pneumonitis or interstitial lung disease, dermatologic reactions, ocular toxicity and embryo-fetal toxicity. [1, 2]

FDA requires confirmatory evidence of clinical benefit. The ongoing randomized Phase 3 OrigAMI-5 trial compares first-line subcutaneous amivantamab plus carboplatin and pembrolizumab with pembrolizumab, platinum chemotherapy and 5-fluorouracil in recurrent or metastatic HNSCC. It measures overall survival and includes head-and-neck symptom and quality-of-life assessments. Its comparative results will address a different treatment setting and regimen from the later-line monotherapy cohort. [2, 5, 6]

What this means for trial teams

Verify the details that determine which patients enter a study. Record the primary tumor site and the pathology supporting HPV classification when relevant. Capture prior treatments and progression dates before enrollment. The rules for an approved indication and a first-line study should be checked separately.

Rehearse the handoff when a scan is missed. Assign responsibility for rescheduling, documenting why the scan was missed, and confirming that the imaging vendor received the complete series. When a patient stops treatment or transfers care, establish who maintains survival follow-up and who reconciles safety reports across sites and vendors. [8]

Keep the patient’s experience visible through follow-up. Where the protocol calls for questionnaires, train sites to explain them in the participant’s preferred language using approved tools and to document why forms were missed. A late or missing assessment can reflect a logistical barrier, worsening symptoms, or a gap in how the site follows patients after treatment ends. Those distinctions affect how the data are interpreted. [7]

For sponsors and CROs, these are concrete interview scenarios for oncology CRAs. Ask how a candidate would resolve conflicting pathology records, trace a missed scan, and route a suspected pneumonitis event. Their answers show how they would help protect the evidence the study is designed to collect.

Sources

  1. FDA oncology approval notice for Rybrevant Faspro
  2. Johnson & Johnson approval announcement and safety data
  3. Journal of Clinical Oncology, pivotal OrigAMI-4 results
  4. ClinicalTrials.gov, OrigAMI-4 (NCT06385080)
  5. ClinicalTrials.gov, OrigAMI-5 (NCT07276399)
  6. OrigAMI-5 design and endpoints, ASCO study poster summary
  7. Lampgen Clinical Insights, making patient-reported outcomes usable
  8. Lampgen Clinical Insights, safety follow-up after missed oncology trial visits

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?